| Symbol | AVIR |
|---|---|
| Name | ATEA PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 125 SUMMER STREET, BOSTON, Massachusetts, 02110, United States |
| Telephone | +1 857 284-8891 |
| Fax | — |
| — | |
| Website | https://www.ateapharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001593899 |
| Description | Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The companys medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. Additional info from NASDAQ: |
2026-06-25 11:00
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Read more
2026-06-23 21:00
Lucidi Bruno 🟡 adjusted position in 64.4K shares (3 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $4.36 Transaction Date: Jun 18, 2026 | Filing ID: 279728
Read more
2026-06-23 21:00
BERGER FRANKLIN M 🟡 adjusted position in 64.4K shares (3 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $4.36 Transaction Date: Jun 18, 2026 | Filing ID: 279726
Read more
2026-06-23 21:00
Berman Howard 🟢 acquired 64.4K shares (2 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $4.36 Transaction Date: Jun 18, 2026 | Filing ID: 279723
Read more
2026-06-23 21:00
DUNCAN BARBARA GAYLE 🟡 adjusted position in 64.4K shares (3 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $4.36 Transaction Date: Jun 18, 2026 | Filing ID: 279721
Read more
2026-06-23 21:00
Polsky Bruce 🟡 adjusted position in 64.4K shares (3 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $4.36 Transaction Date: Jun 18, 2026 | Filing ID: 279719
Read more
2026-06-23 21:00
Murphy Polly A. 🟡 adjusted position in 64.4K shares (3 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $4.36 Transaction Date: Jun 18, 2026 | Filing ID: 279718
Read more
2026-06-23 21:00
Adams Jerome M. 🟡 adjusted position in 64.4K shares (3 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $4.36 Transaction Date: Jun 18, 2026 | Filing ID: 279720
Read more
2026-06-23 21:00
KIRSCH ARTHUR S 🟢 acquired 64.4K shares (2 derivative) of Atea Pharmaceuticals, Inc. (AVIR) at $4.36 Transaction Date: Jun 18, 2026 | Filing ID: 279717
Read more
2026-06-22 20:53
(99% Neutral) ATEA PHARMACEUTICALS, INC. (AVIR) Announces Regulatory Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07272889 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Est… | Phase1 | Healthy Volunteer Study | Completed | 2025-12-04 | 2026-02-17 | ClinicalTrials.gov |
| NCT07037277 | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic H… | Phase3 | HEPATITIS C VIRUS CHRONIC INFECTION | Active_Not_Recruiting | 2025-06-02 | 2027-03-01 | ClinicalTrials.gov |
| NCT07007806 | Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir | Phase1 | Healthy Volunteer Study | Completed | 2025-05-09 | 2025-06-28 | ClinicalTrials.gov |
| NCT06911320 | Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With No… | Phase1 | Healthy Volunteer Study | Recruiting | 2025-04-09 | 2026-05-01 | ClinicalTrials.gov |
| NCT06921941 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and… | Phase1 | Healthy Volunteer Study | Completed | 2025-04-08 | 2025-07-02 | ClinicalTrials.gov |
| NCT06868264 | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic H… | Phase3 | HEPATITIS C VIRUS CHRONIC INFECTION | Active_Not_Recruiting | 2025-04-07 | 2026-12-01 | ClinicalTrials.gov |
| NCT07314346 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphi… | Phase1 | Healthy Volunteer Study | Recruiting | 2025-01-07 | 2026-08-01 | ClinicalTrials.gov |
| NCT06356194 | Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir | Phase1 | Healthy Volunteer Study | Completed | 2024-04-15 | 2024-05-30 | ClinicalTrials.gov |
| NCT06204679 | Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir | Phase1 | Healthy Volunteer Study | Completed | 2023-12-14 | 2024-08-25 | ClinicalTrials.gov |
| NCT05904470 | A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Sub… | Phase2 | Chronic Hepatitis C Virus | Completed | 2023-05-30 | 2025-01-28 | ClinicalTrials.gov |
| NCT05905497 | The Study of Bemnifosbuvir in Healthy Japanese Subjects | Phase1 | Healthy Volunteer Study | Completed | 2023-04-26 | 2023-05-19 | ClinicalTrials.gov |
| NCT05905484 | Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects | Phase1 | Healthy Volunteer Study | Completed | 2023-04-25 | 2023-05-31 | ClinicalTrials.gov |
| NCT05731843 | Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir | Phase1 | Healthy Volunteer Study | Completed | 2023-01-30 | 2023-03-15 | ClinicalTrials.gov |
| NCT05724693 | Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function | Phase1 | Healthy Volunteer | Completed | 2023-01-30 | 2024-04-23 | ClinicalTrials.gov |
| NCT05629962 | SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With C… | Phase3 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) | Completed | 2022-11-25 | 2024-05-30 | ClinicalTrials.gov |
| NCT05618314 | Study of AT-527 in Subjects With Normal and Impaired Renal Function | Phase1 | Healthy Volunteer | Completed | 2022-10-17 | 2024-06-15 | ClinicalTrials.gov |
| NCT05466240 | Study of AT-752 in Patients With Dengue Infection | Phase2 | Dengue Fever | Terminated | 2022-04-29 | 2023-01-19 | ClinicalTrials.gov |
| NCT05366439 | Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model | Phase1 | Dengue | Terminated | 2022-04-22 | 2023-03-16 | ClinicalTrials.gov |
| NCT05256732 | Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal | Phase1 | Healthy Volunteer Study | Completed | 2022-02-22 | 2022-08-23 | ClinicalTrials.gov |
| NCT05154123 | Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) | Phase1 | Healthy Volunteer Study | Completed | 2021-11-16 | 2021-12-23 | ClinicalTrials.gov |
| NCT05137626 | Drug-drug Interaction Study of Digoxin and AT-527 (R07496998) | Phase1 | Healthy Volunteers Study | Completed | 2021-11-03 | 2021-12-12 | ClinicalTrials.gov |
| NCT04309734 | Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HC… | Phase1 | Hepatitis C | Withdrawn | 2021-10-01 | 2022-09-01 | ClinicalTrials.gov |
| NCT05004415 | Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998) | Phase1 | Healthy Volunteer Study | Completed | 2021-07-28 | 2021-08-12 | ClinicalTrials.gov |
| NCT05059080 | A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVI… | — | COVID-19 | Terminated | 2021-06-15 | 2022-03-16 | ClinicalTrials.gov |
| NCT04889040 | Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult a… | Phase3 | COVID-19 | Terminated | 2021-04-28 | 2021-12-02 | ClinicalTrials.gov |
| NCT04877769 | Bronchopulmonary PK of AT-527 (R07496998) | Phase1 | Healthy Volunteer Study | Completed | 2021-04-25 | 2021-08-31 | ClinicalTrials.gov |
| NCT04865445 | Drug-drug Interaction Study of Midazolam and AT-527 (R07496998) | Phase1 | Healthy Volunteer Study | Completed | 2021-04-22 | 2021-05-15 | ClinicalTrials.gov |
| NCT04849299 | Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998) | Phase1 | Healthy Volunteer Study | Completed | 2021-04-18 | 2021-05-10 | ClinicalTrials.gov |
| NCT04722627 | Study of AT-752 in Healthy Subjects | Phase1 | Dengue | Completed | 2021-03-09 | 2021-11-14 | ClinicalTrials.gov |
| NCT04784000 | Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527 | Phase1 | Healthy Volunteer Study | Completed | 2021-03-01 | 2021-04-10 | ClinicalTrials.gov |
| NCT04709835 | Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With… | Phase2 | COVID-19 | Completed | 2021-02-03 | 2021-10-13 | ClinicalTrials.gov |
| NCT04711187 | Study of AT-527 in Healthy Subjects (R07496998) | Phase1 | Healthy Volunteer Study | Completed | 2020-11-02 | 2021-09-15 | ClinicalTrials.gov |
| NCT04396106 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (CO… | Phase2 | COVID-19 | Terminated | 2020-05-26 | 2022-02-28 | ClinicalTrials.gov |
| NCT04019717 | Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Vi… | Phase2 | Hepatitis C | Completed | 2019-06-20 | 2020-03-23 | ClinicalTrials.gov |
| NCT03219957 | Study of AT-527 in Healthy and HCV-Infected Subjects | Phase1 | Chronic Hepatitis C | Completed | 2017-07-06 | 2018-06-20 | ClinicalTrials.gov |
Total clinical trials: 35
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Methadone +BEM/RZR | Other | Phase PHASE1 | Healthy Volunteer Study | RECRUITING | NCT07314346 |
| Buprenorphine/Naloxone + BEM/RZR | Other | Phase PHASE1 | Healthy Volunteer Study | RECRUITING | NCT07314346 |
| Sofosbuvir-Velpatasvir | Other | Phase PHASE3 | HEPATITIS C VIRUS CHRONIC INFECTION | ACTIVE_NOT_RECRUITING | NCT07037277 |
| Bemnifosbuvir-Ruzasvir | Other | Phase PHASE3 | HEPATITIS C VIRUS CHRONIC INFECTION | ACTIVE_NOT_RECRUITING | NCT07037277 |
| AT-527 + rosuvastatin | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05154123 |
| Drug: AT-527 + rosuvastatin | Drug | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05154123 |
| AT-527 (R07496998) | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05004415 |
| Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole | Drug | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Treatment E-Omeprazole 40 mg administered fasting | Drug | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole | Drug | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting | Drug | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Treatment B-Omeprazole 20 mg dose administered fasting | Drug | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting | Drug | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Placebo Comparator | Other | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT03219957 |
| AT-527 | Other | Phase PHASE1 | Chronic Hepatitis C | COMPLETED | NCT03219957 |
| Daclatasvir | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT04019717 |
| AT-527 | Other | Phase PHASE2 | Hepatitis C | COMPLETED | NCT04019717 |
| AT-527 550 mg + midazolam | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04865445 |
| Period 3: AT-527 1100 mg + carbamazepine | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04784000 |
| Period 3: AT-527 550 mg + carbamazepine | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04784000 |
| Period 2: carbamazepine | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04784000 |
| Period 1: AT-527 550 mg | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04784000 |
| AT-527 550 mg + cyclosporine | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04849299 |
| AT-527 | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04877769 |
| AT-527 Formulation 2 | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04711187 |
| Placebo Comparator | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04711187 |
| AT-527 Formulation 1 | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04711187 |
| AT-527 + digoxin | Other | Phase PHASE1 | Healthy Volunteers Study | COMPLETED | NCT05137626 |
| AT-527 | Other | Phase PHASE1 | Hepatitis C | WITHDRAWN | NCT04309734 |
| Placebo | Other | Phase PHASE1 | Hepatitis C | WITHDRAWN | NCT04309734 |
| AT-777 | Other | Phase PHASE1 | Hepatitis C | WITHDRAWN | NCT04309734 |
| Placebo | Other | Phase PHASE1 | Dengue | COMPLETED | NCT04722627 |
| AT-752 | Other | Phase PHASE1 | Dengue | COMPLETED | NCT04722627 |
| AT-527 single dose | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| AT-527 | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| Placebo Comparator fed | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| AT-527 fed | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| Placebo Comparator fasted | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| AT-527 fasted | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| Placebo | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04709835 |
| AT-527 | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04709835 |
| Placebo | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04396106 |
| AT-527 | Other | Phase PHASE2 | COVID-19 | TERMINATED | NCT04396106 |
| Placebo Comparator | Other | Phase PHASE1 | Dengue | TERMINATED | NCT05366439 |
| AT-752 | Other | Phase PHASE1 | Dengue | TERMINATED | NCT05366439 |
| Cohort 2 Ruzasvir + BEM | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05731843 |
| Cohort 1 BEM + Ruzasvir | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05731843 |
| Bemnifosbuvir (BEM) | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05905497 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05905484 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05905484 |
| Bemnifosbuvir (BEM) | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05905484 |
| Placebo | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04889040 |
| RO7496998 | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04889040 |
| Placebo | Other | Phase PHASE2 | Dengue Fever | TERMINATED | NCT05466240 |
| AT-752 | Other | Phase PHASE2 | Dengue Fever | TERMINATED | NCT05466240 |
| Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06356194 |
| Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06356194 |
| Bemnifosbuvir (BEM) | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05724693 |
| AT-527 and Probenecid | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05618314 |
| AT-527 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05618314 |
| Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06204679 |
| Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06204679 |
| Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06204679 |
| Placebo | Other | Phase PHASE3 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) | COMPLETED | NCT05629962 |
| Bemnifosbuvir (BEM) | Other | Phase PHASE3 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection) | COMPLETED | NCT05629962 |
| Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06921941 |
| Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06921941 |
| Methadone +BEM/RZR | Other | Phase PHASE1 | Healthy Volunteer Study | RECRUITING | NCT07314346 |
| Buprenorphine/Naloxone + BEM/RZR | Other | Phase PHASE1 | Healthy Volunteer Study | RECRUITING | NCT07314346 |
| Sofosbuvir-Velpatasvir | Other | Phase PHASE3 | HEPATITIS C VIRUS CHRONIC INFECTION | RECRUITING | NCT07037277 |
| Bemnifosbuvir-Ruzasvir | Other | Phase PHASE3 | HEPATITIS C VIRUS CHRONIC INFECTION | RECRUITING | NCT07037277 |
| Ruzasvir | Other | Phase PHASE2 | Chronic Hepatitis C Virus | COMPLETED | NCT05904470 |
| Bemnifosbuvir | Other | Phase PHASE2 | Chronic Hepatitis C Virus | COMPLETED | NCT05904470 |
| Sofosbuvir-Velpatasvir (SOF/VEL) | Other | Phase PHASE3 | HEPATITIS C VIRUS CHRONIC INFECTION | ACTIVE_NOT_RECRUITING | NCT06868264 |
| Bemnifosbuvir-Ruzasvir (BEM/RZR) | Other | Phase PHASE3 | HEPATITIS C VIRUS CHRONIC INFECTION | ACTIVE_NOT_RECRUITING | NCT06868264 |
| Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07272889 |
| Bemnifosbuvir/Ruzasvir (BEM/RZR) | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07272889 |
| Ethinyl Estradioll/Levonorgestrel (EE/LNG) | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07272889 |
| Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination | Other | Phase PHASE1 | Healthy Volunteer Study | RECRUITING | NCT06911320 |
| Citrate buffer | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT00698425 |
| EyeGate II® Drug Delivery System | OTHER | Phase PHASE1 | Healthy | COMPLETED | NCT00698425 |
| Sodium citrate buffer solution with EyeGate® II System | DRUG | Phase PHASE2 | Dry Eye Syndrome | COMPLETED | NCT00765804 |
| EGP-437 with EyeGate® II System | DRUG | Phase PHASE2 | Dry Eye Syndrome | COMPLETED | NCT00765804 |
| EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System | DRUG | Phase PHASE2 | Uveitis, Anterior | COMPLETED | NCT00694135 |
| EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System | DRUG | Phase PHASE2 | Uveitis, Anterior | COMPLETED | NCT00694135 |
| EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System | DRUG | Phase PHASE2 | Uveitis, Anterior | COMPLETED | NCT00694135 |
| EGP-437 1.6 mA-min at 0.4 with EyeGate® II System | DRUG | Phase PHASE2 | Uveitis, Anterior | COMPLETED | NCT00694135 |
| Sodium citrate buffer solution | DRUG | Phase PHASE3 | Dry Eye | COMPLETED | NCT01129856 |
| Dexamethasone phosphate ophthalmic solution | DRUG | Phase PHASE3 | Dry Eye | COMPLETED | NCT01129856 |
| Placebo Eyedrops | DRUG | Phase PHASE3 | Anterior Uveitis | COMPLETED | NCT01505088 |
| 100 mM sodium citrate buffer solution | DRUG | Phase PHASE3 | Anterior Uveitis | COMPLETED | NCT01505088 |
| Prednisolone Acetate (1%) Eyedrops | DRUG | Phase PHASE3 | Anterior Uveitis | COMPLETED | NCT01505088 |
| 40 mg/mL Dexamethasone phosphate ophthalmic solution | DRUG | Phase PHASE3 | Anterior Uveitis | COMPLETED | NCT01505088 |
| Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA | DRUG | Phase PHASE1 | Patients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal | COMPLETED | NCT02571556 |
| Dexamethasone Phosphate Ophthalmic Solution | DRUG | Phase PHASE1 | Vitrectomy | COMPLETED | NCT02644694 |
| 100 mM Sodium Citrate Buffer | DRUG | Phase PHASE2 | Cataract | COMPLETED | NCT01602068 |
| Dexamethasone Phosphate Ophthalmic | DRUG | Phase PHASE1 | Macular Edema | TERMINATED | NCT02485249 |
| Bandage Contact Lens (BCL) | DEVICE | Approved | Ophthalmology | COMPLETED | NCT03938883 |
| Ocular Bandage Gel (OBG) | DEVICE | Approved | Ophthalmology | COMPLETED | NCT03938883 |
| Nitrofurantoin capsules | DRUG | Phase PHASE2 | Uncomplicated Urinary Tract Infection | COMPLETED | NCT03425396 |
| Omadacycline tablets | DRUG | Phase PHASE2 | Uncomplicated Urinary Tract Infection | COMPLETED | NCT03425396 |
| Levofloxacin | DRUG | Phase PHASE2 | Acute Pyelonephritis | COMPLETED | NCT03757234 |
| Linezolid | DRUG | Phase PHASE3 | Skin Structures and Soft Tissue Infections | WITHDRAWN | NCT00876850 |
| PTK 0796 | DRUG | Phase PHASE3 | Skin Structures and Soft Tissue Infections | WITHDRAWN | NCT00876850 |
| Ocular Bandage Gel | DEVICE | Approved | Corneal Epithelial Wound | COMPLETED | NCT03163641 |
| Acuvue Oasys | DEVICE | Approved | Corneal Epithelial Wound | COMPLETED | NCT03163641 |
| Microdialysis Catheter Insertion | PROCEDURE | Phase PHASE1 | Diabetes | COMPLETED | NCT04144374 |
| Placebos | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT03901482 |
| Dihydroergotamine | DRUG | Phase PHASE1 | Migraine With Aura | COMPLETED | NCT03874832 |
| Omadacycline Oral Tablet [Nuzyra] | DRUG | Phase PHASE4 | Cystic Fibrosis | COMPLETED | NCT04460586 |
| Omadacycline Injection | DRUG | Phase PHASE4 | Microbial Colonization | COMPLETED | NCT05515562 |
| Vancomycin Pill | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06030219 |
| Omadacycline | DRUG | Phase PHASE3 | Bacterial Pneumonia | COMPLETED | NCT02531438 |
| Omadacycline Oral Tablet | DRUG | Phase PHASE2 | Mycobacterium Infections, Nontuberculous | COMPLETED | NCT04922554 |
| Omadacycline Injection [Nuzyra] | DRUG | Phase PHASE4 | Cystic Fibrosis | COMPLETED | NCT04460586 |
| NP-101 | DRUG | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06563375 |
| Methadone +BEM/RZR | DRUG | Phase PHASE1 | Healthy Volunteer Study | NOT_YET_RECRUITING | NCT07314346 |
| Buprenorphine/Naloxone + BEM/RZR | DRUG | Phase PHASE1 | Healthy Volunteer Study | NOT_YET_RECRUITING | NCT07314346 |
| Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) | DRUG | Phase PHASE1 | Healthy Volunteer Study | NOT_YET_RECRUITING | NCT07272889 |
| Bemnifosbuvir/Ruzasvir (BEM/RZR) | DRUG | Phase PHASE1 | Healthy Volunteer Study | NOT_YET_RECRUITING | NCT07272889 |
| Ethinyl Estradioll/Levonorgestrel (EE/LNG) | DRUG | Phase PHASE1 | Healthy Volunteer Study | NOT_YET_RECRUITING | NCT07272889 |
| Sofosbuvir-Velpatasvir | DRUG | Phase PHASE3 | HEPATITIS C VIRUS CHRONIC INFECTION | RECRUITING | NCT07037277 |
| Bemnifosbuvir-Ruzasvir | DRUG | Phase PHASE3 | HEPATITIS C VIRUS CHRONIC INFECTION | RECRUITING | NCT07037277 |
| Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Treatment E-Omeprazole 40 mg administered fasting | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Treatment B-Omeprazole 20 mg dose administered fasting | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT07007806 |
| Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06921941 |
| Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06921941 |
| Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination | DRUG | Phase PHASE1 | Healthy Volunteer Study | RECRUITING | NCT06911320 |
| Sofosbuvir-Velpatasvir (SOF/VEL) | DRUG | Phase PHASE3 | HEPATITIS C VIRUS CHRONIC INFECTION | ACTIVE_NOT_RECRUITING | NCT06868264 |
| Bemnifosbuvir-Ruzasvir (BEM/RZR) | DRUG | Phase PHASE3 | HEPATITIS C VIRUS CHRONIC INFECTION | ACTIVE_NOT_RECRUITING | NCT06868264 |
| Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06356194 |
| Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06356194 |
| Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06204679 |
| Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06204679 |
| Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT06204679 |
| Moxifloxacin | DRUG | Phase PHASE3 | Bacterial Pneumonia | COMPLETED | NCT02531438 |
| Ruzasvir | DRUG | Phase PHASE2 | Chronic Hepatitis C Virus | COMPLETED | NCT05904470 |
| Bemnifosbuvir | DRUG | Phase PHASE2 | Chronic Hepatitis C Virus | COMPLETED | NCT05904470 |
| Cohort 2 Ruzasvir + BEM | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05731843 |
| Cohort 1 BEM + Ruzasvir | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05731843 |
| Bemnifosbuvir (BEM) | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05905497 |
| AT-527 and Probenecid | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05618314 |
| AT-527 single dose | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| Placebo Comparator fed | OTHER | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| AT-527 fed | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| Placebo Comparator fasted | OTHER | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| AT-527 fasted | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05256732 |
| AT-527 + rosuvastatin | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05154123 |
| Drug: AT-527 + rosuvastatin | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05154123 |
| AT-527 + digoxin | DRUG | Phase PHASE1 | Healthy Volunteers Study | COMPLETED | NCT05137626 |
| AT-527 (R07496998) | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT05004415 |
| RO7496998 | DRUG | Phase PHASE3 | COVID-19 | TERMINATED | NCT04889040 |
| AT-527 550 mg + midazolam | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04865445 |
| AT-527 550 mg + cyclosporine | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04849299 |
| Period 3: AT-527 1100 mg + carbamazepine | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04784000 |
| Period 3: AT-527 550 mg + carbamazepine | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04784000 |
| Period 2: carbamazepine | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04784000 |
| Period 1: AT-527 550 mg | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04784000 |
| AT-752 | DRUG | Phase PHASE2 | Dengue Fever | TERMINATED | NCT05466240 |
| AT-527 Formulation 2 | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04711187 |
| AT-527 Formulation 1 | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT04711187 |
| Placebo | OTHER | Phase PHASE2 | Cataract | COMPLETED | NCT03180255 |
| AT-777 | DRUG | Phase PHASE1 | Hepatitis C | WITHDRAWN | NCT04309734 |
| Daclatasvir | DRUG | Phase PHASE2 | Hepatitis C | COMPLETED | NCT04019717 |
| Placebo Comparator | DRUG | Phase PHASE1 | Dengue | TERMINATED | NCT05366439 |
| AT-527 | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05618314 |
Total products: 170